The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors

Background: Immune checkpoint inhibitors combined chemotherapy (ICIC) are widely used for various types of lung cancer in the past decade. However, ICIC related adverse events (AEs) are more serious than immune-related adverse events (irAE) or cytotoxic chemotherapy alone. Objective: This prospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kou, Wen, Lin, Yan Yan, Su, Fei, Xiang, Yue, Qiao, Hui, Wu, Xin’An, Hou, Xiao-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623061/
https://www.ncbi.nlm.nih.gov/pubmed/36330095
http://dx.doi.org/10.3389/fphar.2022.910722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623061/
https://www.ncbi.nlm.nih.gov/pubmed/36330095
http://dx.doi.org/10.3389/fphar.2022.910722

Ejemplares similares